Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Bird, Sarah; Cairns, David; Menzies, Tom; Boyd, Kevin; Davies, Faith; Cook, Gordon; Drayson, Mark; Gregory, Walter; Jenner, Matthew; Jones, John; Kaiser, Martin; Owen, Roger; Jackson, Graham; Morgan, Gareth; Pawlyn, Charlotte
BACKGROUND:Sex differences in the incidence and outcomes of several cancers are well established. Multiple myeloma (MM) is a malignant plasma cell dyscrasia accounting for 2% of all new cancer cases in the UK. There is a clear sex disparity in MM incidence, with 57% of cases in males and 43% in females. The mechanisms behind this are not well understood and the impact of sex on patient outcomes has not been thoroughly explored. PATIENTS AND METHODS/METHODS:We investigated the association of sex with baseline disease characteristics and outcome in 3894 patients recruited to the phase III UK NCRI Myeloma XI trial, in which treatment exposure to lenalidomide predominated. RESULTS:Females were significantly more likely to have the molecular lesions t(14;16) and del(17p) and were more likely to meet the cytogenetic classification of high-risk (HiR) or ultra-high-risk disease (UHiR). There was no difference in progression-free survival (PFS) or overall survival (OS) between the sexes in the overall population. CONCLUSION/CONCLUSIONS:Our data suggest that the genetic lesions involved in the initiation and progression of MM may be different between the sexes. Although females were more likely to have the poor prognosis lesions t(14;16) and del(17p), and were more likely to be assessed as having HiR or UHiR disease, this was not associated with reduced PFS or OS. In female patients the trial treatment may have been able to overcome some of the adverse effects of high-risk cytogenetic lesions. MicroAbstract Multiple myeloma (MM) is more common in males compared to females but the reasons behind this are not well understood and the impact of sex on patient outcomes is unclear. This study demonstrates fundamental differences in genetic lesions underlying the biology of MM between males and females. However, we found that progression-free survival and overall survival were the same in both sexes.
PMID: 34059488
ISSN: 2152-2669
CID: 4936582

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

Weinhold, Niels; Salwender, Hans J; Cairns, David A; Raab, Marc S; Waldron, George; Blau, Igor W; Bertsch, Uta; Hielscher, Thomas; Morgan, Gareth J; Jauch, Anna; Davies, Faith E; Hänel, Mathias; Cook, Gordon; Scheid, Christoph; Houlston, Richard; Goldschmidt, Hartmut; Jackson, Graham; Kaiser, Martin F
Not available.
PMID: 34092058
ISSN: 1592-8721
CID: 4905982

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Verkleij, Christie P M; Broekmans, Marloes E C; van Duin, Mark; Frerichs, Kristine A; Kuiper, Rowan; de Jonge, A Vera; Kaiser, Martin; Morgan, Gareth; Axel, Amy; Boominathan, Rengasamy; Sendecki, Jocelyn; Wong, Amy; Verona, Raluca I; Sonneveld, Pieter; Zweegman, Sonja; Adams, Homer C; Mutis, Tuna; van de Donk, Niels W C J
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies. The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively kills GPRC5D+ MM cell lines in the presence of T cells from both healthy donors or heavily pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone marrow (BM) samples from 45 patients, including those with high-risk cytogenetic aberrations. There was no difference in talquetamab-mediated killing of MM cells from newly diagnosed, daratumumab-naïve relapsed/refractory (median of 3 prior therapies), and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell lysis was accompanied by T-cell activation and degranulation, as well as production of pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were associated with improved talquetamab-mediated lysis of MM cells, whereas an increased proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts were associated with suboptimal killing. In cell line experiments, addition of Tregs to effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also impaired the efficacy of talquetamab. Combination therapy with daratumumab or pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing studies with talquetamab in relapsed/refractory MM.
PMCID:8095149
PMID: 33890981
ISSN: 2473-9537
CID: 4889142

The mutagenic impact of melphalan in multiple myeloma

Maura, Francesco; Weinhold, Niels; Diamond, Benjamin; Kazandjian, Dickran; Rasche, Leo; Morgan, Gareth; Landgren, Ola
The introduction of whole genome and exome sequencing partnered with advanced bioinformatic pipelines has allowed the comprehensive characterization of mutational processes (i.e., mutational signatures) in individual cancer patients. Studies focusing on multiple myeloma have defined several mutational processes, including a recently identified mutational signature (called "SBS-MM1") directly caused by exposure to high-dose melphalan (i.e., autologous stem cell transplant). High-dose melphalan exposure increases both the overall and nonsynonymous mutational burden detected between diagnosis and relapse by ~10-20%. Nevertheless, most of these mutations are acquired within the heterochromatin and late-replicating regions, rarely involving key myeloma driver genes. In this review, we summarize key studies that made this discovery possible, and we discuss potential clinical implications.
PMID: 34012133
ISSN: 1476-5551
CID: 4878732

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Davies, Faith; Rifkin, Robert; Costello, Caitlin; Morgan, Gareth; Usmani, Saad; Abonour, Rafat; Palumbo, Antonio; Romanus, Dorothy; Hajek, Roman; Terpos, Evangelos; Cherepanov, Dasha; Stull, Dawn Marie; Huang, Hui; Leleu, Xavier; Berdeja, Jesus; Lee, Hans C; Weisel, Katja; Thompson, Michael; Boccadoro, Mario; Zonder, Jeffrey; Cook, Gordon; Puig, Noemi; Vela-Ojeda, Jorge; Farrelly, Eileen; Raju, Aditya; Blazer, Marlo; Chari, Ajai
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was followed between 1/2007 and 3/2018 in Optum's deidentified US electronic health records database. Time to next treatment (TTNT) was estimated using Kaplan-Meier methods; regimens were compared using covariate-adjusted Cox proportional hazard models. Seven hundred forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349; KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd, n = 45) in LOTs ≥2 were identified. More patients ≥75 years received IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted median TTNT in LOT ≥ 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In covariate-adjusted analysis, only KRd vs DRd was associated with a significantly higher risk of next LOT initiation/death (HR 1.72; P = 0.0142); no Pd triplet was significantly different vs DPd in LOT ≥ 2. Our data highlight important efficacy/effectiveness gaps between results observed in phase 3 clinical trials and those realized in the RW.
PMID: 33970288
ISSN: 1432-0584
CID: 4878222

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive)

Yong, Kwee L; Hinsley, Samantha; Auner, Holger W; Bygrave, Ceri; Kaiser, Martin F; Ramasamy, Karthik; De Tute, Ruth M; Sherratt, Debbie; Flanagan, Louise; Garg, Mamta; Hawkins, Stephen; Williams, Catherine; Cavenagh, Jamie; Rabin, Neil K; Croft, James; Morgan, Gareth; Davies, Faith; Owen, Roger G; Brown, Sarah R
The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. MUKfive was a phase II controlled, parallel group trial that randomised patients (2:1) to KCd (201) or VCd (99); responding patients on carfilzomib were randomised to maintenance carfilzomib (69) or no further treatment (72). Primary endpoints were (i) very good partial response (VGPR, non-inferiority, OR 0.8) at 24 weeks, and (ii) progression-free survival (PFS). More participants achieved ≥VGPR with carfilzomib compared to bortezomib (40.2% vs. 31.9%, OR=1.48, 90%CI:0.95,2.31; non-inferior), with a trend for particular benefit in adverse risk disease. KCd was associated with higher overall response (≥PR, 84.0% vs. 68.1%, OR=2.72, 90%CI:1.62,4.55, p=0.001). Neuropathy (grade ≥3 or ≥2 with pain) was more common with bortezomib (19.8% vs. 1.5%, p.
PMID: 33910333
ISSN: 1592-8721
CID: 4873752

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma

Wong, Kwan Yeung; Morgan, Gareth J; Boyle, Eileen M; Cheng, Alfred Sze Lok; Yip, Kevin Yuk-Lap; Chim, Chor Sang
Enhancer DNA methylation and expression of MYBPHL was studied in multiple myeloma (MM). By bisulfite genomic sequencing, among the three CpGs inside the MYBPHL enhancer, CpG1 was significantly hypomethylated in MM cell lines (6.7-50.0%) than normal plasma cells (37.5-75.0%) (P = 0.007), which was negatively correlated with qPCR-measured MYBPHL expression. In RPMI-8226 and WL-2 cells, bearing the highest CpG1 methylation, 5-azadC caused enhancer demethylation and expression of MYBPHL. In primary samples, higher CpG1 methylation was associated with lower MYBPHL expression. By luciferase assay, luciferase activity was enhanced by MYBPHL enhancer compared with empty vector control, but reduced by site-directed mutagenesis of each CpG. RNA-seq data of newly diagnosed MM patients showed that MYBPHL expression was associated with t(11;14). MOLP-8 cells carrying t(11;14) express the highest levels of MYBPHL, and its knockdown reduced cellular proliferation and increased cell death. Herein, as a proof-of-concept, our data demonstrated that the MYBPHL enhancer, particularly CpG1, was hypomethylated and associated with increased MYBPHL expression in MM, which was implicated in myelomagenesis.
PMCID:7997988
PMID: 33772052
ISSN: 2045-2322
CID: 4858322

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Oben, Bénedith; Froyen, Guy; Maclachlan, Kylee H; Leongamornlert, Daniel; Abascal, Federico; Zheng-Lin, Binbin; Yellapantula, Venkata; Derkach, Andriy; Geerdens, Ellen; Diamond, Benjamin T; Arijs, Ingrid; Maes, Brigitte; Vanhees, Kimberly; Hultcrantz, Malin; Manasanch, Elisabet E; Kazandjian, Dickran; Lesokhin, Alexander; Dogan, Ahmet; Zhang, Yanming; Mikulasova, Aneta; Walker, Brian; Morgan, Gareth; Campbell, Peter J; Landgren, Ola; Rummens, Jean-Luc; Bolli, Niccolò; Maura, Francesco
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n = 15) are characterized by later initiation in the patient's life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.
PMID: 33767199
ISSN: 2041-1723
CID: 4823652

Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma [Case Report]

Demonchy, Jordane; Cordier, Camille; Fréalle, Emilie; Demarquette, Hélène; Herbaux, Charles; Escure, Guillaume; Willaume, Alexandre; Van De Wyngaert, Zoé; Noel, Marie-Pierre; Facon, Thierry; Faure, Karine; Caro, Jessica; Morgan, Gareth; Davies, Faith E; Alfandari, Serge; Bories, Claire; Boyle, Eileen M
PMID: 33642203
ISSN: 2152-2669
CID: 4806942

Positive selection as the unifying force for clonal evolution in multiple myeloma [Letter]

Diamond, Benjamin; Yellapantula, Venkata; Rustad, Even H; Maclachlan, Kylee H; Mayerhoefer, Marius; Kaiser, Martin; Morgan, Gareth; Landgren, Ola; Maura, Francesco
PMID: 33483619
ISSN: 1476-5551
CID: 4788272